Abstract
Interleukin (IL)-2 was originally purified as a “T-cell growth factor” (TCGF) inducing the survival of human T-lymphocytes in vitro (1). Shortly after this, a 19-kDa molecule was definitively named IL-2 (2,3) and was shown early to interact with a cell surface receptor identified by the anti-Tac monoclonal antibody (mAb) (4,5). This mAb was later shown to recognize the α-chain (CD25) low-affinity receptor complex conferring high-affinity binding (10-11 M) to the (β/γ-chain IL-2 receptor shared with other cytokines (6,7). In 1983, the first DNA clone of IL-2 was obtained (8).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Morgan, D.A., Ruscetti, F.W., and Gallo, R. (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193, 1007–1008.
Smith, K.A. (1980) T-cell growth factor. Immunol. Rev. 51, 337–357.
Watson, J. and Mochizuki, D. (1980) Interleukin 2: a class of T cell growth factors. Immunol. Rev. 51, 257–278.
Robb, R.J., Munck, A., and Smith, K.A. (1981) T Cell growth factor receptors. Quantitation, specificity, and biological relevance. J. Exp. Med. 154, 1455–1474.
Depper, J.M., Leonard, W.J., Robb, R.J., Waldmann, T.A., and Greene W.C. (1983) Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J. Immunol. 131, 690–696.
Leonard, W.J. and O’Shea, J.J. (1998) Jaks and STATs: biological implications. Annu. Rev. Immunol. 16, 293–322.
Waldmann, T.A. and Tagaya, Y. (1999) The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 17, 19–49.
Taniguchi, T., Matsui, H., Fujita, T., Takaoka, C, Kashima, N., Yoshimoto, R., et al. (1983) Structure and expression of a cloned cDNA for human interleukin-2. Nature 302, 305–310.
Schwartz, D.H., Skowron, G., and Merigan, T.C. (1991) Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J. Acquired Immune Defic. Syndrome 4, 11–23.
Kovacs, J.A., Baseler, M., Dewar, R.J., Vogel, S., Davey, R.T., Jr., Falloon, J., et al. (1995) Increases in CD4 T lymphocytes with intermittent courses of interleukin- 2 in patients with human immunodeficiency virus infection. A preliminary study. N. Engl. J. Med. 332, 567–575.
Kovacs, J.A., Vogel, S., Albert, J.M., Falloon, J., Davey, R.T., Jr., Walker, R.E., et al. (1996) Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335, 1350–1356.
Wood, R., Montoya, J.G., Kundu, S.K., Schwartz, D.H., and Merigan, T.C. (1993) Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J. Infect. Dis. 167,519–525.
Jacobson, E.L., Pilaro, F., and Smith, K.A. (1996) Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc. Natl. Acad. Sci. USA 93, 10,405–10,410.
Teppler, H., Kaplan, G., Smith, K.A., Montana, A.L., Meyn, P., and Cohn, Z.A. (1993) Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection. J. Exp. Med. 111, 483–492.
McMahon, D.K., Armstrong, J.A., Huang, X.L., Rinaldo, C.R., Jr., Gupta, P., Whiteside, T.L., et al. (1994) A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine. AIDS 8, 59–66.
Mazza, P., Bocchia, M., Tumietto, F., Costigliola, P., Coronado, O., Bandini, G., et al. (1992) Recombinant interleukin-2 (rIL-2) in acquired immune deficiency syndrome (AIDS): preliminary report in patients with lymphoma associated with HIV infection. Eur. J. Haematol. 49, 1–6.
Schnittman, S.M., Vogel, S., Baseler, M., Lane, H.C., and Davey, R.T., Jr. (1994) A phase I study of interferon-alpha 2b in combination with interleukin- 2 in patients with human immunodeficiency virus infection. J. Infect. Dis. 169, 981–989.
Klimas, N., Patarca, R., Walling, J., Garcia, R., Mayer, V., Moody, D., et al. (1994) Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion. AIDS 8, 1073–1081.
Bernstein, Z.P., Porter, M.M., Gould, M., Lipman, B., Bluman, E.M., Stewart, C.C., et al. (1995) Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 86, 3287–3294.
De Paoli, P., Zanussi, S., Simonelli, C, Bortolin, M.T., D’Andrea, M., Crepaldi, C, et al. (1997) Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. J. Clin. Invest. 100, 2737–2743.
Levy, Y., Capitant, C, Houhou, S., Carriere, I., Viard, J.P., Goujard, C, et al. (1999) Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet 353, 1923–1929.
Zanussi, S., Simonelli C, Bortolin M.T., D’Andrea M., Crepaldi C, Vaccher E., et al. (1999) Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2. Clin. Exp. Immunol. 116, 486–492.
Losso, M.H., Belloso, W.H., Emery, S., Benetucci, J.A., Cahn, P.E., Lasala, M.C., et al. (2000) A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3. J. Infect. Dis. 181, 1614–1621.
Arno, A., Ruiz, L., Juan, M., Jou, A., Balague, M., Zayat, M.K., et al. (1999) Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with <250/(iL CD4 T cells and undetectable plasma viral load. J. Infect. Dis. 180, 56–60.
David, D., Nait-Ighil, L., Dupont, B., Maral, J., Gachot, B., and Theze, J. (2001) Rapid effect of interleukin-2 therapy in human immunodeficiency virus- infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. J. Infect. Dis. 183, 730–735.
Zanussi, S., Simonelli, C, Bortolin, M.T., D’Andrea, M., Comar, M., Tirelli, U., et al. (1999) Dynamics of provirus load and lymphocyte subsets after interleukin 2 treatment in HIV-infected patients. AIDS Res. Hum. Retroviruses 15, 97–103.
Simonelli, C, Zanussi, S., Sandri, S., Comar, M., Lucenti, A., Talamini, R., et al. (1999) Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection. J. Acquired Immune Defic. Syndrome Hum. Retrovir. 20, 20–27.
Hengge, U.R., Goos, M., Esser, S., Exner, V., Dotterer, H., Wiehler, H., et al. (1998) Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 12, F225-F234.
De Paoli, P., Zanussi, S., Caggiari, L., Bortolin M.T., D’Andrea M., Simonelli C. et al. (1999) Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2. J. Clin. Immunol. 19, 317–325.
Davey, R.T., Jr., Chaitt, D.G., Albert, J.M., Piscitelli, S.C., Kovacs, J.A., Walker, R.E., et al. (1999) A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J. Infect. Dis. 179, 849–858.
Carr, A., Emery S., Lloyd A., Hoy J., Garsia R., French M., et al. (1998) Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group. J. Infect. Dis. 178, 992–999.
Weissman, D., Dybul, M., Daucher, M.B., Davey, R.T., Jr., Walker, R.E., and Kovacs J.A. (2000) Interleukin-2 up-regulates expression of the human immunodeficiency virus fusion coreceptor CCR5 by CD4+ lymphocytes in vivo. J. Infect. Dis. 181, 933–938.
Blanco, J., Cabrera, C., Jou, A., Ruiz, L., Clotet, B. and Este, J.A. (1999) Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. AIDS 13, 547–555.
Zou, W., Foussat, A., Houhou, S., Durand-Gasselin, I., Dulioust, A., Bouchet, L., et al. (1999) Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV- infected patients treated with interleukin-2. ANRS 048 IL-2 Study Group. AIDS 13, 455–463.
Horak, I., Lohler, J., Ma, A., and Smith, K.A. (1995) Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol. Rev. 148, 35–44.
Hunig, T. and Schimpl, A. (1998) The IL-2 deficiency syndrome. A lethal disease caused by abnormal lymphocyte survival, in Cytokine Knockouts (Durum, S.K. and Muegge, K., eds.), Humana, Totowa, NJ, pp. 1–19.
Refaeli, Y., Van Parijs, L., London, C.A., Tschopp, J., and Abbas, A.K. (1998) Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8, 615–623.
Espinoza-Delgado, I., Bosco, M.C., Musso, T., Gusella, G.L., Longo, D.L., and Varesio, L. (1995) Interleukin-2 and human monocyte activation. J. Leukocyte Biol. 57, 13–19.
Ben Aribia, M.H., Leroy, E., Lantz, O., Metivier, D., Autran, B., Charpentier, B., et al. (1987) rIL 2-induced proliferation of human circulating NK cells and T lymphocytes: synergistic effects of IL 1 and IL 2. J. Immunol. 139, 443–451.
Oliva, A., Kinter, A.L., Vaccarezza, M., Rubbert, A., Catanzaro, A., Moir, S., et al. (1998) Natural killer cells from human immunodeficiency virus (HlV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J. Clin. Invest. 102, 223–231.
Mule, J.J., Shu, S., Schwarz, S.L., and Rosenberg, S.A. (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225, 1487–1489.
Yu, T.K., Caudell, E.G., Smid, C., and Grimm, E. A. (2000) IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J. Immunol. 164, 6244–6251.
Liu, C.C., Perussia, B., and Young, J.D. (2000) The emerging role of IL-15 in NK-cell development. Immunol. Today 21, 113–116.
Lanier, L.L. and Bakker, A.B. (2000) The ITAM-bearing transmembrane adaptor DAP 12 in lymphoid and myeloid cell function. Immunol. Today 21, 611–614.
Mingari, M.C., Ponte, M., Vitale, C., Bellomo, R. and Moretta, L. (2000) Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Hum. Immunol. 61, 44–50.
Rosenberg, S.A. (1984) Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J. Biol. Response Modifiers 3, 501–511.
Rosenberg, S.A. (2000) Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J. Sci. Am. 6(Suppl 1), S2–7.
Barre-Sinoussi, F., Chermann, J.C., Rey, F., Nugeyre, M.T., Chamaret, S., Gruest, J., et al. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868–871.
Gallo, R.C., Sarin, P.S., Gelmann, E.P., Robert-Guroff, M., Richardson, E., Kalyanaraman, V.S., et al. (1983) Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220, 865–867.
Hazan, U., Thomas, D., Alcami, J., Bachelerie, F., Israel, N., Yssel, H., et al. (1990) Stimulation of a human T-cell clone with anti-CD3 or tumor necrosis factor induces NF-kappa B translocation but not human immunodeficiency virus 1 enhancer-dependent transcription. Proc. Natl. Acad. Sci. USA 87, 7861–7865.
Zhang, Z., Schuler, T., Zupancic, M., Wietgrefe, S., Staskus, K.A., Reimann, K.A., et al. (1999) Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286, 1353–1357.
Vyakarnam, A., McKeating, J., Meager, A., and Beverley, P.C. (1990) Tumour necrosis factors (oc,p) induced by HIV-1 in peripheral blood mononuclear cells potentiate virus replication. AIDS, 4, 21–27.
Ramilo, O., Bell, K.D., Uhr, J.W., and Vitetta, E.S. (1993) Role of CD25+ and CD25-T cells in acute HIV infection in vitro. J. Immunol. 150, 5202–5208.
Kinter, A.L., Poli, G., Fox, L., Hardy, E., and Fauci, A.S. (1995) HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J. Immunol. 154, 2448–2459.
Kinter, A.L., Bende, S.M., Hardy, E.C., Jackson, R., and Fauci, A.S. (1995) Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression. Proc. Natl. Acad. Sci. USA 92, 10,985–10,989.
Lusso, P. (2000) Chemokines and viruses: the dearest enemies. Virology 273, 228–240.
Walker, C.M., Moody, D.J., Stites, D.P., and Levy, J.A. (1986) CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234, 1563–1566.
Poli, G. (1999) Laureate ESCI award for excellence in clinical science 1999. Cytokines and the human immunodeficiency virus: from bench to bedside. European Society for Clinical Investigation. Eur. J. Clin. Invest. 29, 723–732.
Simmons, G., Reeves, J.D., Hibbitts, S., Stine, J.T., Gray, P.W., Proudfoot, A.E., and Clapham, P.R. (2000) Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol. Rev. 177, 112–126.
Loetscher, P., Seitz M., Baggiolini, M., and Moser, B. (1996) Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J. Exp. Med. 184, 569–577.
Plana, M., Garcia, F., Gallart, T., Tortajada, C., Soriano, A., Palou, E., et al. (2000) Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 14, 1921–1933.
Kutza, J., Hayes, M.P., and Clouse, K.A. (1998) Interleukin-2 inhibits HIV-1 replication in human macrophages by modulating expression of CD4 and CC-chemokine receptor-5. AIDS 12, F59-F64.
Bleul, C.C., Wu, L., Hoxie, J.A., Springer, T.A., and Mackay, C.R. (1997) The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 94, 1925–1930.
Unutmaz, D., Xiang, W., Sunshine, M.J., Campbell, J., Butcher, E., and Littman D.R. (2000) The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse. J. Immunol. 165, 3284–3292.
Inngjerdingen, M., Damaj, B., and Maghazachi, A.A. (2001) Expression and regulation of chemokine receptors in human natural killer cells. Blood 97, 367–375.
Kern, P., Toy, J., and Dietrich, M. (1985) Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS. Blut 50, 1–6.
Ernst, M., Kern, P., Flad, H.D., and Ulmer, A.J. (1986) Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome (AIDS) and AIDS- related complex (ARC) on phenotypes and functions of peripheral blood mononuclear cells (PBMC). J. Clin. Immunol. 6, 170–181.
Volberding, P., Moody, D.J., Beardslee, D., Bradley, E.C., and Wofsy, C.B. (1987) Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. AIDS Res. Hum. Retroviruses 3, 115–124.
Schwartz, D.H. and Merigan, T.C. (1990) Interleukin-2 in the treatment of HIV disease. Biotherapy 2, 119–136.
Tambussi, G., Ghezzi, S., Nozza, S., Vallanti, G., Magenta, L., Guffanti, M., et al. (2001) Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: a controlled study of 3 IL-2 regimens with antiviral drug therapy. J. Infect. Dis. 183, 1476–1484.
Davey, R.T., Jr., Chaitt, D.G., Piscitelli, S.C., Wells, M., Kovacs, J.A., Walker, R.E., et al. (1997) Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 175, 781–789.
Miller, K.D., Spooner, K., Herpin, B.R., Rock-Kress, D., Metcalf, J.A., Davey, R.T., Jr., et al. (2001) Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion. Clin. Immunol. 99, 30–42.
Emery, S., Capra W.B., Cooper D.A., Mitsuyasu R.T., Kovacs J.A., Vig P., et al. (2000) Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J. Infect. Dis. 182, 428–34.
Davey, R.T., Jr., Murphy R.L., Graziano F.M., Boswell S.L., Pavia A.T., Cancio M., et al. (2000) Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. JAMA 284, 183–189.
Lentsch, A.B., Miller, F.N., and Edwards, M.J. (1999) Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Cancer Immunol. Immunother. 47, 243–248.
Lane, H.C., Siegel, J.P., Rook, A.H., Masur, H., Gelmann, E.P., Quinnan, G.V., and Fauci, A.S. (1984) Use of interleukin-2 in patients with acquired immunodeficiency syndrome. J. Biol. Response Modifiers 3, 512–516.
Piscitelli, S.C., Forrest A., Vogel S., Chaitt D., Metcalf J., Stevens R., et al. (1998) Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 64, 492–98.
Khatri, V.P., Fehniger T.A., Baiocchi R.A., Yu F., Shah M.H., Schiller D.S., et al. (1998) Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J. Clin. Invest. 101, 1373–1378.
Piscitelli, S.C., Wells, M.J., Metcalf, J.A., Baseler, M., Stevens, R. and Davey, R.T., Jr. (1996) Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients. Pharmacotherapy 16, 754–759.
Piscitelli, S.C., Vogel, S., Figg, W.D., Raje, S., Forrest, A., Metcalf, J.A., et al. (1998) Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus. Pharmacotherapy 18, 1212–1216.
Lafeuillade, A., Poggi, C, Chadapaud, S., Hittinger, G., Chouraqui, M., Pisapia, M., et al. (2001) Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. J. Acquired Immune Defic. Syndrome 26, 44–55.
Katlama, C, Duvivier, C, Chouquet, C, Autran, B., Carcelain, G., De Sa, M., et al. (2000) ILSTIM (ANRS 082)—a randomized comparative open-label study of interleukin-2 (IL2) in patients with CD4 <200 despite effective HAART. 7th Conference on Retroviruses and Opportunistic Infections, p. 177 (abstract).
De Boer, R.J. and Perelson, A.S. (1998) Target cell limited and immune control models of HIV infection: a comparison. J. Theor.Biol. 190,201–214.
de Jong, M.D., de Boer, R.J., de Wolf, F., Foudraine, N.A., Boucher, C.A., Goudsmit, J., et al. (1997) Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS 11, F79-F84.
Davey, R.T., Jr., Bhat N., Yoder C, Chun T.W., Metcalf J.A., Dewar R., et al. (1999) HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96, 15,109–15,114.
Bovolenta, C, Camorali, L., Lorini, A.L., Vallanti, G., Ghezzi, S., Tambussi, G., et al. (1999) In vivo administration of recombinant IL-2 to individuals infected by HIV down-modulates the binding and expression of the transcription factors ying-yang-1 and leader binding protein-1/Late simian virus 40 factor. J. Immunol. 163, 6892–6897.
Margolis, D.M., Somasundaran, M., and Green, M.R. (1994) Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production. J. Virol. 68, 905–910.
Bovolenta, C, Camorali, L., Lorini, A.L., Ghezzi, S., Vicenzi, E., Lazzarin, A. and Poli, G. (1999) Constitutive activation of STATs upon In vivo human immunodeficiency virus infection. Blood 94, 4202–4209.
Pandolfi, F., Pierdominici, M, Marziali, M., Bernardi, M., Antonelli, G., Galati, V., et al. (2000) Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HA ART. Clin. Immunol. 94, 153–159.
Chun, T.W., Engel D., Mizell S.B., Hallahan C.W., Fischette M., Park S., et al. (1999) Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5,651–655.
Chun, T.W., Davey, R.T., Jr., Ostrowski, M., Shawn Justement, J., Engel, D., Mullins, J.I., et al. (2000) Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti- retroviral therapy. Nat. Med. 6, 757–761.
Kovacs, J.A., Imamichi H., Vogel S., Metcalf J.A., Dewar R.L., Baseler M., et al. (2000) Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression. J. Infect. Dis. 182, 1063–1069.
Dianzani, F., Antonelli, G., Aiuti, F., Turriziani, O., Riva, E., Capobianchi, M.R., et al. (2000) The number of HIV DNA-infected mononuclear cells is reduced under HAART plus recombinant IL-2. IRHAN Study Group. Antiviral Res. 45, 95–99.
Clark, A.G., Holodniy, M., Schwartz, D.H., Katzenstein, D.A., and Merigan, T.C. (1992) Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration. J. Acquired Immune Defic. Syndrome 5, 52–59.
Pantaleo, G., Koenig, S., Baseler, M., Lane, H.C., and Fauci, A.S. (1990) Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population. J. Immunol. 144, 1696–1704.
Liu, Z., Cumberland, W.G., Hultin, L.E., Prince, H.E., Detels, R., and Giorgi, J.V. (1997) Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J. Acquired Immune Defic. Syndrome Hum. Retrovir. 16, 83–92.
Shearer, G.M. (1998) HIV-induced immunopathogenesis. Immunity 9, 587–593.
Shevach, E.M. (2000) Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 18, 423–449.
Salomon, B., Lenschow, D.J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., et al. (2000) B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431–440.
Read, S., Malmstrom, V., and Powrie F. (2000) Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295–302.
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., et al. (2000) Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303–310.
David, D., Bani, L., Moreau, J.L., Treilhou, M.P., Nakarai, T., Joussemet, M., et al. (1998) Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. Proc. Natl. Acad. Sci. USA 95, 11,348–11,353.
Moreau, J.L., Chastagner, P., Tanaka, T., Miyasaka, M., Kondo, M., Sugamura, K., et al. (1995) Control of the IL-2 responsiveness of B lymphocytes by IL-2 and IL-4. J. Immunol. 155, 3401–3408.
Teppler, H., Kaplan, G., Smith, K., Cameron, P., Montana, A., Meyn, P., et al. (1993) Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J. Infect. Dis. 167, 291–298.
Vaith, P., Maas D., Feigl, D., Hauke, G., Lang, B., Oepke, G., et al. (1985) In vitro and in vivo studies with interleukin 2 (IL-2) and various immunostimulants in a patient with AIDS. Immun. Infekt. 13, 51–63.
Kelleher, A.D., Roggensack, M., Emery, S., Carr, A., French, M.A., and Cooper, D.A. (1998) Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens. Clin. Exp. Immunol. 113, 85–91.
Aladdin, H., Larsen, C.S., Moller, B.K., Ullum, H., Buhl, M.R., Gerstoft, J., et al. (2000) Effects of subcutaneous interleukin-2 therapy on phenotype and function of peripheral blood mononuclear cells in human immunodeficiency virus infected patients. Scand. J. Immunol. 51, 168–175.
Zou, W., Foussat, A., Capitant, C, Durand-Gasselin, I., Bouchet, L., Galanaud, P., et al. (1999) Acute activation of CD8+ T lymphocytes in interleukin-2-treated HIV-infected patients. ANRS-048 IL-2 Study Group. Agence Nationale de Recherches sur le SIDA. J. Acquired Immune Defic Syndrome 22, 31–38.
Piscitelli, S.C., Amatea, M.A., Vogel, S., Bechtel, C, Metcalf, J.A., and Kovacs, J.A. (1996) Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines. Antimicrob. Agents Chemother. 40, 161–165.
Fortis, C, Soldini, L., Ghezzi, S., Colombo, S., Tambussi, G., Vicenzi, E., et al. (2002) Tumor necrosis factor-α, interleukin-2 (IL-2), and soluble IL-2 receptor levels in human immunodeficiency virus-1 infected individuals receiving intermittent cycles of IL-2. AIDS Res. Hum. Retrovir. 18, 491–499.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Poli, G., Fortis, C., Lazzarin, A., Tambussi, G. (2003). Interleukin-2 for the Treatment of HIV Infection. In: Kotb, M., Calandra, T. (eds) Cytokines and Chemokines in Infectious Diseases Handbook. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-309-5_24
Download citation
DOI: https://doi.org/10.1007/978-1-59259-309-5_24
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-247-6
Online ISBN: 978-1-59259-309-5
eBook Packages: Springer Book Archive